Real-life evaluation of novel forced expiratory ratios with asthma exacerbations and symptoms
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001399" target="_blank" >RIV/00064190:_____/25:10001399 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10506377
Result on the web
<a href="https://doi.org/10.1016/j.anai.2025.08.015" target="_blank" >https://doi.org/10.1016/j.anai.2025.08.015</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.anai.2025.08.015" target="_blank" >10.1016/j.anai.2025.08.015</a>
Alternative languages
Result language
angličtina
Original language name
Real-life evaluation of novel forced expiratory ratios with asthma exacerbations and symptoms
Original language description
Background Small airway dysfunction is an important treatable trait in persistent asthma but remains poorly captured by conventional spirometry. The (forced expiratory volume in 3 seconds [FEV3]-FEV1)/forced vital capacity (FVC) and FEV3/FEV6 ratios have been proposed as novel markers of peripheral airflow limitation. Objective To investigate the relationship between (FEV3-FEV1)/FVC and FEV3/FEV6 with symptom control and the frequency of severe exacerbations in patients with moderate-to-severe asthma. Methods Clinical, physiological, and biomarker data were collected from adults with Global Initiative for Asthma-defined moderate-to-severe asthma visiting a specialist severe asthma center in Scotland, United Kingdom. Associations between spirometric and oscillometric parameters with clinically relevant outcomes were retrospectively analyzed using multivariate models. Results A total of 294 patients were included in the analysis. The (FEV3-FEV1)/FVC and FEV3/FEV6 ratios were not significantly associated with asthma symptoms or severe exacerbation rates. Conversely, traditional measures such as FEV1/FVC (adjusted odds ratio [95% CI], 2.11 [1.27-3.50]; P < .01), forced expiratory flow rate between 25% and 75% of the FVC/FVC (2.11 [1.27-3.50]; P < .01), and oscillometric Rrs(5-20) (1.90 [1.14-3.16]; P < .05) were significantly associated with more than or equal to 2 exacerbations in the previous year. High coefficient of determination (r(2)) values were observed between FEV1/FVC with (1) (FEV3-FEV1)/FVC (r(2) = 0.61) and (2) FEV3/FEV6 (r(2) = 0.83), suggesting overlapping aspects of lung function being measured. There was a weak correlation between FEV1/FVC and Rrs(5-20) values (r(2) = 0.08) indicating that these parameters assess unique aspects of lung function and mechanics. Conclusion In moderate-to-severe asthma, the (FEV3-FEV1)/FVC and FEV3/FEV6 ratios were not independently associated with exacerbation risk or symptom control and did not provide additional clinical value compared with conventional lung function measures (c) 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30225 - Allergy
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
ISSN
1081-1206
e-ISSN
1534-4436
Volume of the periodical
135
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
nestránkováno
UT code for WoS article
001630611500012
EID of the result in the Scopus database
2-s2.0-105022130896